fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Cefprozil

All products: general benefit

Ran-Cefprozil · DIN 02293579 · 250 mg/5 mL · Oral suspension-75mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Ran-Cefprozil · DIN 02293579 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-09-04 Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Cefprozil: Formulary list price $14.54 per unit (the source does not state the unit; exact figure $14.5350). What the ministry pays, not the patient.

Ministry pays: $14.5350 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02293579)

Source record
DIN 02293579: Ran-Cefprozil Raw flags: sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id RAN Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $14.5350; ministry $14.5350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293579 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77893
Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350 Cefzil · DIN 02163683 · not recorded
Shortage status: resolved shortage (ended October 16, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293579
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01D, J01DC): coverage varies; not interchangeable

  • Cefuroxime axetil (Ceftin): general benefit, not a benefit
  • Cefoxitin (Mefoxin): not a benefit
  • Cefadroxil (Duricef): general benefit, not a benefit
  • Cefixime (Suprax): general benefit
  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cephalexin (Ceporex): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE SPC-Cefprozil (cefprozil) is indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Upper Respiratory Tract Pharyngitis / tonsillitis caused by group A ß-hemolytic (GABHS) Streptococcus pyogenes. Substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present, although no case was reported during its evaluation in over 978 pediatric and 831 adult patients in controlled clinical trials. Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis. Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, (beta-lactamase positive and negative strains), and Moraxella (Branhamella) catarrhalis. Skin And Skin Structure Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes. Urinary Tract Uncomplicated urinary tract infections (including acute cystitis) caused by Escherichia coli, Pr SPC-Cefprozil – Product Monograph … https://pdf.hres.ca/dpd_pm/00080833.PDF PM date: JUN 18, 2025 Source product: SPC-CEFPROZIL; DIN 02293528; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.